<DOC>
	<DOCNO>NCT02989649</DOCNO>
	<brief_summary>The purpose study observe alogliptin alogliptin fixed-dose combination ( FDCs ) utilization pattern , well clinical response treatment alogliptin alogliptin FDCs , standard clinical practice .</brief_summary>
	<brief_title>Non-Interventional Study Use Alogliptin Alogliptin Fixed-Dose Combinations With Pioglitazone With Metformin Standard Clinical Practice</brief_title>
	<detailed_description>The drug study study call alogliptin alogliptin FDCs . Alogliptin alogliptin FDCs research treat people diabetes mellitus type 2 . This study look glycosylated hemoglobin ( HbA1c ) level dynamic participant diabetes mellitus type 2 . The study enroll approximately 1199 patient . Alogliptin alogliptin FDCs prescribed physician part participant ' T2DM treatment program ( independent participation study ) . This multi-center study conduct China Hong Kong . The overall duration study observation approximately 6 month , loss follow-up death , whichever occur first . Participants make multiple visit clinic per regular doctor 's appointment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Has diagnosis T2DM . 2 . Has make decision , along his/her treat physician , begin treatment alogliptin alogliptin fixeddose combination ( FDCs ) . 3 . Has glycated hemoglobin ( HbA1c ) value record 3 month initiation treatment alogliptin alogliptin FDCs . 4 . Alogliptin alogliptin FDCs prescribe accord approve label China Hong Kong . 1 . Has gestational diabetes type 1 diabetes mellitus . 2 . Has use Dipeptidyl peptidase4 inhibitor ( DPPIV inhibitor ) Glucagon like peptide1 agonist ( aGLP1 ) within 3 month prior start alogliptin alogliptin FDCs treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>